Receptor News and Research

RSS

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

However, with the waning of the immune response, it is not clear if these older people respond to the vaccine as well as younger individuals do. A recent study explored this question and found that though the antibody levels were somewhat lower in this group, they were still robust. This is a promising observation.

26 Apr 2021

Hormonal therapies for breast and prostate cancers increase the risk of heart attack, stroke

The hormonal therapies used to treat many breast and prostate cancers raise the risk of a heart attack and stroke, and patients should be monitored regularly and receive treatment to reduce risk and detect problems as they occur.

26 Apr 2021

Using estrogen to target drug-resistant breast cancer in mice

Researchers at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) hope to make estrogen therapy a more accessible treatment option for breast cancer patients who could benefit from it.

26 Apr 2021

SARS-CoV-2 limits type I and type III IFN protein biogenesis

New research led by Roy Parker of the University of Colorado Boulder finds that SARS-CoV-2 prevents the IFN response despite an increased presence of IFN-encoding mRNAs by suppressing transcriptional processes. Inhibition of IFN mRNAs triggers degradation from the activation of RNase L and the SARS-CoV-2 protein Nsp1.

26 Apr 2021

Researchers harness the body's own ability to block pain

Fentanyl, oxycodone, morphine--these substances are familiar to many as a source of both pain relief and the cause of a painful epidemic of addiction and death.

26 Apr 2021

Potential new COVID vaccine from Australia

Phase 1 trial results published in The Lancet Infectious Diseases found a new subunit vaccine —an MF59-adjuvanted subunit vaccine using recombinant spike glycoprotein stabilized in a prefusion conformation by a novel molecular clamp — targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was safe and effective in producing an antigen-specific response in healthy adults.

26 Apr 2021

Two repurposed drugs and a blue dye show potential as SARS-CoV-2 entry inhibitors

A new multidisciplinary study from Australia, published in the open-access journal mBio, shows that three compounds used to treat cystic fibrosis, dry eye, and a specific medical dye may lead to future strategies for the treatment of coronavirus disease (COVID-19).

25 Apr 2021

Study characterizes anti-inflammatory effect of strawberry geranium on the skin

Strawberry geranium (Saxifraga stolonifera) has been used in Japan as a herbal medicine to treat wounds and swelling, and continues to be an ingredient in food and cosmetics.

23 Apr 2021

Researchers develop computer model to predict the impact of individual receptors on brain activity

Researchers regard the overall distribution of receptors in the brain – the receptome – as a new approach for computer models that reproduce the function of the brain, and for diagnostics and therapy of mental disorders.

23 Apr 2021

Researchers create a cell library to study how various sugars bind to and interact with receptors

Most infectious bacteria and viruses bind to sugars on the surface of our cells. Now researchers from the University of Copenhagen have created a library of tens of thousands of natural cells containing all the sugars found on the surface of our cells.

23 Apr 2021

New imaging technique captures movies of receptors on the surface of living cells

A new imaging technique developed by scientists at Columbia University Vagelos College of Physicians and Surgeons and St. Jude Children's Research Hospital captures movies of receptors on the surface of living cells in unprecedented detail and could pave the way to a trove of new drugs.

23 Apr 2021

The Native Antigen Company Launches SARS-CoV-2 Neutralisation Assay Development Kit

The Native Antigen Company today announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit.

From The Native Antigen Company 23 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Artificial intelligence helps identify new key-lock pairs against coronavirus

The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them.

23 Apr 2021

Experimental drug reverses key symptoms of Alzheimer's disease in mice

Researchers at Albert Einstein College of Medicine have designed an experimental drug that reversed key symptoms of Alzheimer's disease in mice.

22 Apr 2021

Mutations in estrogen receptor gene associated with worse outcomes after breast cancer treatment

A small proportion of women who receive anti-estrogen treatment after breast cancer surgery have worse outcomes. This is associated with mutations in the estrogen receptor gene, according to a study from Lund University now published in JNCI Cancer Spectrum.

22 Apr 2021

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

New research has been released, which focuses on the transmission and prevalence of SARS-CoV-2 in New Zealand, through a blood donor serosurvey.

22 Apr 2021

Metabolic testing of COVID-19 patients through skin imprints

There is, therefore, a great need to understand how the illness can be diagnosed using more convenient and inexpensive methods. A new study posted to the medRxiv preprint server reveals the potential role of skin imprints to test for biomarkers that indicate a diagnosis of COVID-19 in a non-invasive way.

22 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

What do we know about the origin and evolution of SARS-CoV-2?

A new study examines the origin and continuing evolution of SARS-CoV-2 in the human and animal co-hosts in an attempt to help prepare for future destructive outbreaks.

21 Apr 2021

Receptor News and Research

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

Hormonal therapies for breast and prostate cancers increase the risk of heart attack, stroke

Using estrogen to target drug-resistant breast cancer in mice

SARS-CoV-2 limits type I and type III IFN protein biogenesis

Researchers harness the body's own ability to block pain

Potential new COVID vaccine from Australia

Two repurposed drugs and a blue dye show potential as SARS-CoV-2 entry inhibitors

Study characterizes anti-inflammatory effect of strawberry geranium on the skin

Researchers develop computer model to predict the impact of individual receptors on brain activity

Researchers create a cell library to study how various sugars bind to and interact with receptors

New imaging technique captures movies of receptors on the surface of living cells

The Native Antigen Company Launches SARS-CoV-2 Neutralisation Assay Development Kit

Celastrol shows potential anti-SARS-CoV-2 activity

Artificial intelligence helps identify new key-lock pairs against coronavirus

Experimental drug reverses key symptoms of Alzheimer's disease in mice

Mutations in estrogen receptor gene associated with worse outcomes after breast cancer treatment

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

Metabolic testing of COVID-19 patients through skin imprints

SARS-CoV-2 vaccine with single-cycle adenovirus vector

What do we know about the origin and evolution of SARS-CoV-2?

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News